Literature DB >> 32361797

CT-Guided Core Biopsy for Peripheral Sub-solid Pulmonary Nodules to Predict Predominant Histological and Aggressive Subtypes of Lung Adenocarcinoma.

Ping-Chung Tsai1, Yi-Chen Yeh2,3, Po-Kuei Hsu1,2, Chun-Ku Chen2,4, Teh-Ying Chou2,3, Yu-Chung Wu5,6.   

Abstract

BACKGROUND: Adenocarcinoma is the most common type of lung cancer, and pre-operative biopsy plays an important role to determine its major subtypes. As proposed by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) in 2011, the predominant histological subtype of adenocarcinoma is an indicator of outcomes and recurrence rate. However, the value of CT-guided core biopsy in predicting the predominant subtype and detecting the presence of an aggressive subtype of adenocarcinoma, peripheral sub-solid nodule, has less been discussed.
METHODS: We retrospectively reviewed 318 consecutive peripheral sub-solid nodules that underwent percutaneous CT-guided lung biopsy and surgical resection, between October 2015 and December 2018 and were diagnosed as adenocarcinoma with histological subtype. The subtyping results from biopsy and surgical pathology were compared to evaluate the concordance rate.
RESULTS: The overall concordance rate between biopsy and surgical pathology in determining the predominant histological subtype was 64%. Better concordance was found in small tumors (≤ 2 cm), in predicting either predominant histology (χ2 = 7.091, P = 0.008) or high grade adenocarcinoma, micropapillary and/or solid subtype, MIP-SOL (χ2 = 22.301, P < 0.001). The analysis of ground glass opacity (GGO) component (C/T ratio) obtained significantly higher accuracy in the pure GGO group than in the other two groups in predicting predominant histology or high grade adenocarcinoma (χ2 = 17.560, P < 0.001 and χ2 = 61.938, P < 0.001, respectively).
CONCLUSIONS: CT-guided core biopsies provide additional value in predicting the histological subtype of lung adenocarcinoma after surgical resection, especially in small tumors (≤ 2 cm) or an initially pure GGO group.

Entities:  

Mesh:

Year:  2020        PMID: 32361797     DOI: 10.1245/s10434-020-08511-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  22 in total

1.  Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Authors:  Song Gao; Seth Stein; Elena N Petre; Waleed Shady; Jeremy C Durack; Carole Ridge; Prasad Adusumilli; Natasha Rekhtman; Stephen B Solomon; Etay Ziv
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

2.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

3.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

4.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

5.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Authors:  Akihiko Yoshizawa; Noriko Motoi; Gregory J Riely; Cami S Sima; William L Gerald; Mark G Kris; Bernard J Park; Valerie W Rusch; William D Travis
Journal:  Mod Pathol       Date:  2011-01-21       Impact factor: 7.842

6.  Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.

Authors:  Jonathan E Leeman; Andreas Rimner; Joseph Montecalvo; Meier Hsu; Zhigang Zhang; Donata von Reibnitz; Kelly Panchoo; Ellen Yorke; Prasad S Adusumilli; William Travis; Abraham J Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-09-29       Impact factor: 7.038

7.  Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma.

Authors:  Tae Hee Kim; Darren Buonocore; Elena Nadia Petre; Jeremy C Durack; Majid Maybody; Rocio P Johnston; William D Travis; Prasad S Adusumilli; Stephen B Solomon; Etay Ziv
Journal:  Ann Thorac Surg       Date:  2019-04-12       Impact factor: 4.330

Review 8.  Sublobar Resection: Ongoing Controversy for Treatment for Stage I Non-Small Cell Lung Cancer.

Authors:  Joanna Sesti; Jessica S Donington
Journal:  Thorac Surg Clin       Date:  2016-08       Impact factor: 1.750

9.  Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.

Authors:  Sarina Bains; Takashi Eguchi; Arne Warth; Yi-Chen Yeh; Jun-Ichi Nitadori; Kaitlin M Woo; Teh-Ying Chou; Hendrik Dienemann; Thomas Muley; Jun Nakajima; Aya Shinozaki-Ushiku; Yu-Chung Wu; Shaohua Lu; Kyuichi Kadota; David R Jones; William D Travis; Kay See Tan; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2018-09-22       Impact factor: 15.609

10.  Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance.

Authors:  Yusuke Takahashi; Takashi Eguchi; Koji Kameda; Shaohua Lu; Raj G Vaghjiani; Kay See Tan; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Oncotarget       Date:  2018-11-06
View more
  7 in total

1.  Use of Computed Tomography-Guided Percutaneous Biopsy of Invasive Non-Mucinous Lung Adenocarcinoma to Predict the Degree of Histological Differentiation.

Authors:  Dehao Liu; Lichun Chen; Xiaoping Wang; Yikai Lin; Jianwei Gu
Journal:  Clin Med Insights Oncol       Date:  2022-06-07

2.  Prognostic histologic subtyping of dominant tumor in resected synchronous multiple adenocarcinomas of lung.

Authors:  Ping-Chung Tsai; Chia Liu; Yi-Chen Yeh; Chun-Ku Chen; Po-Kuei Hsu; Hui-Shan Chen; Chien-Sheng Huang; Chih-Cheng Hsieh; Han-Shui Hsu; Biing-Shiun Huang
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

3.  CT-Guided Percutaneous Core Needle Biopsy in Typing and Subtyping Lung Cancer: A Comparison to Surgery.

Authors:  Hanfei Zhang; Sufang Tian; Shan Wang; Songmei Liu; Meiyan Liao
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Application of rapid on‑site evaluation in computed tomography‑guided percutaneous transthoracic needle biopsy of pulmonary nodules of ≤2.0 cm in diameter.

Authors:  Dongxu Wang; Qing Zhang; Yuguang Wang; Wei Dou; Guoxu Ding; Qiuting Wen; Ying Han; Youli Du; Bo Li
Journal:  Exp Ther Med       Date:  2022-09-07       Impact factor: 2.751

5.  Predictors of Invasiveness in Adenocarcinoma of Lung with Lepidic Growth Pattern.

Authors:  Timothy J Young; Ramin Salehi-Rad; Reza Ronaghi; Jane Yanagawa; Puja Shahrouki; Bianca E Villegas; Brian Cone; Gregory A Fishbein; William D Wallace; Fereidoun Abtin; Igor Barjaktarevic
Journal:  Med Sci (Basel)       Date:  2022-06-22

6.  Efficacy and Safety Analysis of Multislice Spiral CT-Guided Transthoracic Lung Biopsy in the Diagnosis of Pulmonary Nodules of Different Sizes.

Authors:  Huitong Liu; Xiao Yao; Bingqiang Xu; Wei Zhang; Yu Lei; Xiaolong Chen
Journal:  Comput Math Methods Med       Date:  2022-08-25       Impact factor: 2.809

7.  Supplementary benefits of CT-guided transthoracic lung aspiration biopsy for core needle biopsy.

Authors:  Jia-Huan He; Jia-Xing Ruan; Ying Lei; Zhi-Dan Hua; Xiang Chen; Da Huang; Cheng-Shui Chen; Xu-Ru Jin
Journal:  Front Microbiol       Date:  2022-09-14       Impact factor: 6.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.